PubMed · 10927701
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
A J Dietrich. 2000. Depression management programs.. https://doi.org/10.1001/archfami.9.8.689
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
A new model for multivariate non-normal longitudinal data is proposed. In a first step, each longitudinal series of data corresponding to a given response is modelled separately using a copula to relate the marginal distributions of the response at each time of observation. In a second step, at each observation time, the conditional (on the past) distributions of each response are related using another copula describing the relationship between the corresponding variables. Note that there is no need to consider the same family of distributions for these response variables. The technique is illustrated in a dose titration safety study on a new antidepressant. The haemodynamic effect on diastolic blood pressure, systolic blood pressure and heart rate is studied. These three responses are measured repeatedly over time on ten healthy volunteers during the dose escalation. The available covariates are sex and the concentration of drug in the plasma at time of measurement.
Explore the source record for details and available documents.
This review describes female sexual dysfunction (FSD) as an adverse effect to pharmacological treatment. FSD covers libido, arousal, orgasm, and pain problems. The existing knowledge of the influence of medication upon female sexual function is very sparse. Treatment with SSRIs and other antidepressants may cause decreased libido and organism problems. Antipsychotic treatment often causes libido, lubrication, and orgasm problems. Spironolactone may cause decreased libido and impaired lubrication. Whether antihypertensives, H2-receptor antagonists and sex hormones have sexual adverse effects has not been clarified properly. Some drugs, such as bupropion and sildenafil, may enhance the sexual function, but further studies have to be carried out. The need for further research on the topic is stressed.